Sagenite

Sagenite is an antimycotactic drug, the international non-proprietary name: mesodiethylethylenedibenzo-sulfonate. Trade names - Sagenite, Sigetin. Produced in the Russian Federation.

Indications Sagenite

The main indication for the use of the drug Sagenitis is the climacteric syndrome, that is, the whole complex of vegetative-vascular, mental and metabolic-endocrine disorders that occur in women against the background of extinction of the hormonal function of the ovaries and the general age involution of the organism.

The drug is recommended for the removal of such manifestations of menopause, as:

• "Tides" to the head, upper limbs and upper body,
• hyperhidrosis (increased sweating),
• thinning of the skin and wrinkles,
• brittle nails,
• dystrophy of the urinary tract mucosa,
• psychosomatic climacteric syndrome (sleep disturbance, irritability, mood instability, etc.).

Release form

The form of the preparation is a tablet. One tablet contains 100 mg of active ingredient sygetin (Sygethin) - dipotassium dihydrate mesodiethylethylenedibenzenesulfonate. Sigetin is a biologically active substance obtained synthetically (a derivative of 1,4-naphthoquinone), it differs in its chemical structure from hormones of natural origin, but has a pronounced hormonal effect.

Pharmacodynamics

Most of menopausal menopausal symptoms in women are associated with inadequate estrogen production. Estrogen refers to steroid hormones and is produced by the ovaries. It stimulates the development of women's reproductive organs, the formation of secondary female sex characteristics, promotes timely rejection of the endometrium and regular monthly bleeding.

After menopause, a decrease in the level of estrogen in many women causes vasomotor and thermoregulatory instability ("hot flushes" of the blood to the skin of the face), sleep disorders, partial atrophy of the urogenital system, osteoporosis.

The active substance of the preparation Saghenit influences the functioning of the endocrinological network, which connects the hypothalamus, pituitary and ovaries and controls the cyclic changes in the ovaries and endometrium (the inner mucosa of the uterus body).

Sagenite reduces the gonadotropic function of the pituitary gland, that is, the production of gonadotropic hormones (follicle-stimulating, luteotropic and luteinizing), which affect the function of the ovary woman. In addition, the substance sygetin has an effect on the hypothalamic center, whose functions include maintaining the optimal level of metabolism, regulating the body's temperature balance, the work of the cardiovascular, digestive, excretory, respiratory systems and endocrine glands.

The manufacturer of the drug Saghenit indicates that this drug does not have an estrogenic effect on the target organs, that is, does not fill the deficiency of endogenous estrogens. At the same time, Sagenite increases uterine contractions and increases placental blood flow - blood circulation in the mother-placenta-fetus system (during pregnancy).

It should be noted that the analog preparation Sigetin (with the same active substance) is recommended as a stimulant of labor.

Pharmacokinetics

Data on the pharmacokinetics of Sagenite were not provided by the manufacturers of this drug.

Dosing and administration

The preparation Saghenite should be taken as prescribed by the doctor in such dosage: one tablet within 24 hours - regardless of the meal. The maximum permissible daily dose is two tablets. The recommended course of treatment is 30-40 days.

Use Sagenite during pregnancy

Use of Sagenite during pregnancy and lactation is not provided.

Contraindications

Among the contraindications to the use of the preparation Saghenit, there is an increased sensitivity to the drug and uterine bleeding not associated with the menstrual cycle (metrorrhagia). With caution the drug is prescribed in the presence of such pathologies as renal insufficiency, violations of the liver function, abnormally elevated levels of lipids and lipoproteins in the blood (hyperlipoproteinemia).

Side effects Sagenite

Taking a drug to relieve symptoms of menopause in women rarely has undesirable side effects, which can manifest as dizziness, nausea, vomiting, skin rashes, swelling of the eyelids, yellowing of the mucous membranes, sclera and skin (cholestatic jaundice), uterine bleeding (metrorrhagia ).

[1]

Overdose

Overdose of Sagenite is manifested by uterine bleeding and acute blood loss (hemorrhagic shock). In case of an overdose, the drug should be withdrawn, with significant blood loss, blood transfusion or parenteral administration of blood substitutes.

Interactions with other drugs

Sagenite enhances the action of diuretics ( diuretics); the effect of drugs that normalize the heart rhythm (antiarrhythmic); drugs that lower blood pressure (hypotensive); drugs that inhibit blood clotting (anticoagulants).

The therapeutic effect of the Sagenium is increased by drugs containing thyroid hormones, as well as vitamin B9 (folic acid).

[2], [3], [4]

Storage conditions

Conditions for storing the drug: dry place inaccessible to children, temperature not higher than + 25 ° С.

Shelf life

Shelf life - 2 years from the date of issue. After the expiration date, the use of the drug Sagenite is unacceptable.